A diverse team has assembled to create new treatments utilizing proprietary protein conjugation technology.
Catena Biosciences uses a novel protein conjugation method to bring breakthroughs in biological therapeutics, autoimmune disorders and vaccine development.
Spinning out of the Berkeley Lab that won the Nobel Prize for CRISPR, Catena’s technology allows the attachment of any two proteins together faster and more selectively than any competing method, and create complicated constructs far beyond the capability of genetic fusions found in the industry today.
Since Catena’s technology focuses on the naturally occurring amino acids tyrosine and cysteine, its applicability is robust. Their platform can be used to create complicated constructs far beyond the capability of genetic fusions or chemical attachment.
By bringing people and protein together, Catena’s revolutionary protein coupling technology will create new therapies for cancer, vaccines, and to retrain the immune system to cure autoimmune disorders.